Evolution of Treatment-Emergent Resistant Variants in Telaprevir Phase 3 Clinical Trials | Zendy

James C. Sullivan | Zendy; Sandra De Meyer | Zendy; Doug J. Bartels | Zendy; Inge Dierynck | Zendy; Eileen Z. Zhang | Zendy; Joan Spanks | Zendy; Ann M. Tigges | Zendy; Anne Ghys | Zendy; Jennifer Dorrian | Zendy; Nathalie Adda | Zendy; Emily C. Martin | Zendy; Maria Beumont | Zendy; Ira M. Jacobson | Zendy; Kenneth E. Sherman | Zendy; Stefan Zeuzem | Zendy; Gastón Picchio | Zendy; Tara L. Kieffer | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Evolution of Treatment-Emergent Resistant Variants in Telaprevir Phase 3 Clinical Trials

Author(s) -

James C. Sullivan,

Sandra De Meyer,

Doug J. Bartels,

Inge Dierynck,

Eileen Z. Zhang,

Joan Spanks,

Ann M. Tigges,

Anne Ghys,

Jennifer Dorrian,

Nathalie Adda,

Emily C. Martin,

Maria Beumont,

Ira M. Jacobson,

Kenneth E. Sherman,

Stefan Zeuzem,

Gastón Picchio,

Tara L. Kieffer

Publication year - 2013

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cit226

Subject(s) - telaprevir , medicine , protease inhibitor (pharmacology) , hepatitis c virus , genotype , clinical trial , ns3 , hepacivirus , virology , virus , ribavirin , viral load , gene , genetics , biology , antiretroviral therapy

Telaprevir (TVR), a hepatitis C virus (HCV) NS3/4A protease inhibitor, has been approved to treat genotype 1 HCV. To understand the clinical impact of TVR-resistant variants, we analyzed samples from patients in phase 3 clinical trials to determine the frequency and retention of TVR-resistant variants in patients who did not achieve sustained virologic response (SVR).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research